Literature DB >> 20384749

Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre- or post-treatment triple combination cream.

Se-Yeong Jeong1, Jae-Bin Shin, Un-Cheol Yeo, Won-Serk Kim, Il-Hwan Kim.   

Abstract

BACKGROUND: Topical triple combination (TC) treatment is considered the primary approach to melasma. Recently, collimated low-fluence 1,064-nm Q-switched neodymium-doped yttrium aluminum garnet (Nd:YAG) laser treatment has attracted attention as an alternative approach.
OBJECTIVES: To compare the clinical efficacy and adverse effects of low-fluence Q-switched Nd:YAG laser when performed before and after treatment with topical TC using a split-face crossover design.
METHODS: Thirteen patients with melasma received topical treatment with TC cream or 1,064-nm Q-switched Nd:YAG laser treatment on opposite sides of the face for 8 weeks, and then treatments were reversed for 8 weeks. Responses were evaluated using the Melasma Area and Severity Index scoring system, spectrophotometry measurements, and a subjective self-assessment method.
RESULTS: After 16 weeks, better results were seen in subjective assessments when laser treatment was used after 8 weeks of topical TC treatment than before usage of TC. There were no significant adverse effects with the laser treatments.
CONCLUSIONS: Laser treatment after topical TC cream was found to be safer and more effective than the post-treatment use of topical agents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20384749     DOI: 10.1111/j.1524-4725.2010.01523.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  17 in total

1.  Combination of Q-Switched Nd:YAG and Fractional Erbium:YAG Lasers in Treatment of Melasma: A Randomized Controlled Clinical Trial.

Authors:  Shiva Alavi; Ehsan Abolhasani; Sharin Asadi; Mohammadali Nilforoushzadeh
Journal:  J Lasers Med Sci       Date:  2017-01-08

2.  The dual toning technique for melasma treatment with the 1064 nm Nd: YAG laser: A preliminary study.

Authors:  Hy Kang; Jh Kim; Bc Goo
Journal:  Laser Ther       Date:  2011

Review 3.  Confetti-like Sparing: A Diagnostic Clinical Feature of Melasma.

Authors:  Douglas C Wu; Richard E Fitzpatrick; Mitchel P Goldman
Journal:  J Clin Aesthet Dermatol       Date:  2016-02

4.  Analysis of Clinical Features and Treatment Outcomes Using 1,064-nm Nd-YAG Laser with Topical Hydroquinone in Patients with Riehl's Melanosis: A Retrospective Study in 10 Patients.

Authors:  Chong Won Choi; Gwanghyun Jo; Dong Hun Lee; Seong Jin Jo; Cheol Lee; Je-Ho Mun
Journal:  Ann Dermatol       Date:  2019-02-28       Impact factor: 1.444

5.  Intense Pulsed Light and Low-Fluence Q-Switched Nd:YAG Laser Treatment in Melasma Patients.

Authors:  Se Young Na; Soyun Cho; Jong Hee Lee
Journal:  Ann Dermatol       Date:  2012-07-25       Impact factor: 1.444

6.  Lasers are not Effective for Melasma in Darkly Pigmented Skin.

Authors:  Kabir Sardana; Vijay K Garg
Journal:  J Cutan Aesthet Surg       Date:  2014-01

7.  Treatment of Melasma with the Photoacoustic Twin Pulse Mode of Low-Fluence 1,064 nm Q-Switched Nd:YAG Laser.

Authors:  Jee Young Kim; Misoo Choi; Chan Hee Nam; Ji Seok Kim; Myung Hwa Kim; Byung Cheol Park; Seung Phil Hong
Journal:  Ann Dermatol       Date:  2016-05-25       Impact factor: 1.444

8.  Treatment of Postinflammatory Pigmentation Due to Acne with Q-Switched Neodymium-Doped Yttrium Aluminum Garnet In 78 Indian Cases.

Authors:  Vijay P Zawar; Madhuri Agarwal; Biju Vasudevan
Journal:  J Cutan Aesthet Surg       Date:  2015 Oct-Dec

9.  Lasers for treatment of melasma and post-inflammatory hyperpigmentation.

Authors:  Pooja Arora; Rashmi Sarkar; Vijay K Garg; Latika Arya
Journal:  J Cutan Aesthet Surg       Date:  2012-04

10.  Proposing Melasma Severity Index: A New, More Practical, Office-based Scoring System for Assessing the Severity of Melasma.

Authors:  Imran Majid; Inaamul Haq; Saher Imran; Abid Keen; Khalid Aziz; Tasleem Arif
Journal:  Indian J Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.